This article examines the global accessibility challenges of Lenacapavir, a groundbreaking HIV prevention drug that demonstrated extraordinary efficacy in clinical trials. It contrasts two perspectives: Gilead Sciences claims rapid progress in making the drug available through voluntary licensing agreements with six generic manufacturers for 120 countries, while critics led by Dr. Andrew Hill argue these agreements exclude crucial middle-income countries representing 23% of global HIV infections. The controversy centers on pricing and accessibility, with Hill calculating generic production could cost $40-95 annually per patient versus Gilead's $40,000 treatment price in high-income markets. Critics suggest compulsory licensing may be necessary if Gilead doesn't modify its approach, citing Colombia's 2024 precedent with dolutegravir. The article notes political shifts threaten HIV funding programs, potentially impacting global distribution efforts. Read More

Explore the global collaboration landscape for Kv1.3-targeting drugs in 2024, highlighting key clinical players, regional licensing preferences, and strategic partner selection. Learn how to identify ideal license-out opportunities and leverage Unibest's international BD expertise to maximize your drug pipeline's value. Read More

Patent Cliff Looms – Can Kv1.3 Take the Baton for the Next Wave of Drug Licensing?1. Introduction: The Patent Cliff Is Coming, Leaving Market Voids“Patent cliff” refers to the sharp revenue drop pharma companies face when blockbuster drug patents expire, opening the door to generic competition. Read More

Explore the future beyond GLP-1 drugs in diabetes and obesity treatment with amylin analogs. This article dives into the clinical promise, market opportunities, key challenges, and licensing strategies for amylin-based therapies, highlighting why they may redefine the next wave of metabolic medicine. Learn how Unibest supports pharma companies in licensing and accelerating amylin drug development. Read More

This article explores the growing preference for small molecule GLP-1 receptor agonists in developing countries, driven by cost sensitivity, infrastructure limitations, and the need for scalable oral therapies for diabetes and obesity. It examines the economic and clinical advantages of small molecules over biologics, analyzes emerging market dynamics, and outlines how Unibest leverages its sourcing, regulatory, and export expertise to support global access. The piece also reviews current pipeline innovations and the future potential of affordable GLP-1 drugs in underserved regions. Read More

Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a breakthrough in obesity and type 2 diabetes treatment. This article explores its synergistic mechanism, superior clinical outcomes, and global market potential. It also highlights how Unibest supports global pharma companies with API sourcing, licensing, and regulatory services in the incretin drug space. Read More

EpimAb Biotherapeutics has successfully implemented the NewCo model through two significant deals in 2024-2025: licensing EMB-06 to Vignette Bio and a T-cell engaging molecule to Juri Biosciences. Read More

Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More

New Approval of Olaparib IndicationOn January 2nd, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza® (Generic name: olaparib) has received approval for a new indication in China. Read More